Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Dogwood's expanded pipeline includes three late-stage assets: Halneuron ®, currently in Phase 2b development for chemotherapy ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A heat receptor therapy may aid in dry eye relief. Additionally, medication waste has more than tripled since 2016.

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...

Researchers at Memorial Sloan Kettering Cancer Center (“MSK”) developed DANYELZA® (naxitamab-gqgk), which is exclusively licensed by MSK to Y-mAbs. MSK has institutional financial interests in the ...

Neuropathic pain affects more than 20 million people in the U.S., and at least a quarter of these cases are puzzling for ...

A recent study found that patients’ perioperative pain experience was a better predictor of chronic postsurgical pain than acute pain intensity.

Find out about the groundbreaking MDMA clinical trial for chronic nerve pain. Discover how this study aims to test the impact of MDMA compared to a placebo.